27 results about "Astragaloside" patented technology

The invention provides lactobacillus reuteri GY-18 and application thereof in increasing the content of astragaloside, and belongs to the technical field of microorganisms, fermentation and natural product biotransformation. The lactobacillus reuteri GY-18 capable of improving the content of astragaloside in a fermented astragalus membranaceus product is obtained through screening, the lactobacillus reuteri GY-18 is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC M 20252796, and the lactobacillus reuteri GY-18 can be used for improving the content of astragaloside in the fermented astragalus membranaceus product. The lactobacillus reuteri GY-18 can secrete acetylxylan esterase for promoting conversion of astragaloside into astragaloside IV, has efficient specificity on conversion of astragaloside into astragaloside IV, and is high in conversion capacity; according to the method, the content of astragaloside IV is remarkably increased within 24 hours in a semi-solid state fermentation mode, and the method has good practicability.

The invention belongs to the technical field of biomedical materials. The invention provides a composite nano preparation for treating diabetic ulcer and promoting wound healing and a preparation method thereof. The preparation method comprises the following steps: mixing tetra (4-carboxyl phenyl) porphyrin and FeCl3. 6H2O for reaction, then adding a mixed solution composed of benzoic acid and 3, 5-dicarboxyphenylboronic acid for reaction, and then performing centrifugal drying; dispersing in water, adding a chloroplatinic acid solution, stirring, adding a sodium borohydride solution, continuously stirring, and centrifugally drying; stirring with a mixture of curcumin, flavonoid glycoside and astragaloside in ethanol, and carrying out centrifugal drying; and finally, stirring with glucose oxidase in water, and centrifugally drying. The composite nano preparation provided by the invention has an excellent antibacterial effect on multi-drug-resistant bacteria, can effectively destroy a biological membrane, can well treat diabetic ulcer and promote wound healing, and has a relatively good application prospect.

The invention discloses a method for extracting astragaloside IV from astragalus membranaceus, and relates to the technical field of traditional Chinese medicine extraction.The method comprises the following steps that firstly, astragalus membranaceus powder is pretreated and then put into an extraction kettle of a supercritical CO2 extraction device; in the first stage, an entrainer a is used for extraction for 15-20 min under the conditions that the pressure is 30-35 MPa, the temperature is 50-54 DEG C and the CO2 flow speed is 0.8-0.9 L / min; in the second stage, an entrainer b is used for extraction for 75-85 min under the conditions that the pressure is 28-33 MPa, the temperature is 52-56 DEG C and the CO2 flow rate is 0.6-0.7 L / min; in the third stage, an entrainer c is used for extraction for 15-20 min under the conditions that the pressure is 20-25 MPa, the temperature is 42-46 DEG C and the CO2 flow rate is 0.4-0.5 L / min; and finally collecting the extract and purifying to obtain a pure product of astragaloside. The method for extracting astragaloside IV from astragalus membranaceus, provided by the invention, has relatively high extraction rate and purity.

The invention relates to glycyrrhizic acid astragaloside composite hydrogel, and belongs to the technical field of medical materials. The invention aims to solve the problems that astragaloside is poor in water solubility, and hydrogel prepared by a traditional method is uneven in drug entrapment and insufficient in healing promoting performance. According to the technical scheme, the preparation method is characterized in that glycyrrhizic acid is subjected to ultrasonic pretreatment to form nano-micelles, astragaloside is entrapped forcibly through high-pressure homogenization, and finally the composite hydrogel with a compact structure is obtained through programmed cooling. The glycyrrhizic acid astragaloside composite hydrogel prepared by the invention is mainly used for preparing dressings or medicines for promoting skin wound healing, and is particularly suitable for treating diabetic wounds.

The invention discloses an application of a compound composition containing astragaloside IV in preparation of a medicine for resisting plateau fatigue, and the compound composition containing astragaloside IV is prepared from the following raw materials in parts by weight: 500 to 2000 parts of astragaloside IV, 5000 to 20000 parts of ginsenoside Rg1, 2 to 5 parts of vitamin D3 and 30000 to 150000 parts of puerarin. Animal experiments prove that the compound composition can relieve plateau exercise fatigue, improve the hypoxia tolerance, exercise fatigue resistance and oxidative stress resistance of a body and improve the comprehensive exercise performance of the body. According to the invention, the defect of single-component efficacy is overcome, a compound preparation is designed in a targeted manner, an innovative and feasible compound combination is provided, and a new scheme is provided for promoting athletic performance under plateau hypoxia.

The invention discloses a preparation method of a radix astragali extracting solution with high antioxidant activity and the extracting solution, and aims to solve the problems of low extraction rate of active substances and inaccurate detection of antioxidant activity in the prior art. According to the method, five factors including ethanol content, extracting solution multiple and the like are taken as key variables, U10 * (108) uniform test design is adopted, the DPPH free radical scavenging rate is accurately determined by combining an electron paramagnetic resonance technology, and the contents of astragaloside, general flavone and polysaccharide are synchronously detected. A quantitative model is established through multivariate linear regression analysis, and the optimal process parameters are determined: the ethanol content is 80%, the extracting solution multiple is 4, the temperature is 85 DEG C, the time is 1.5 h, and the extraction time is 1 time. The DPPH free radical scavenging rate of the extracting solution prepared through the technology is larger than or equal to 92.75%, polysaccharide is larger than or equal to 12520 mg / L, total flavone is larger than or equal to 323.77 mg / L, astragaloside is larger than or equal to 257 mg / L, synergistic efficient extraction of multiple components is achieved, and the extracting solution is suitable for industrial production.

The application relates to application of astragaloside B to preparation of a medicine for treating oligoasthenospermia and the medicine, and belongs to the field of traditional Chinese medicine. Through animal experiments, it is shown that the astragaloside B significantly improves the quantity and quality of rat sperms, and no obvious side effects are observed during the treatment. The astragaloside B has the effects of inhibiting oxidation stress, promoting secretion of testosterone, regulating secretion of follicle stimulating hormone and luteinizing hormone, promoting growth and maturation of sperms, effectively improving sperm function, and enhancing the repair capacity of the body to testicular injury. Moreover, no obvious side effects are observed during the treatment of the astragaloside B on oligoasthenospermia.

The application provides a preparation method of cycloastragenol and relates to the technical field of biology.The preparation method of the cycloastragenol comprises the following steps: preparing a mixed solution of astragaloside, xylosidase and GSM microbial agent, and preparing the cycloastragenol through a conversion reaction.The preparation method can realize 100% conversion of the astragaloside through the synergistic effect of the GSM microbial agent and the xylosidase, and the preparation method is simple and efficient, and the prepared cycloastragenol has high yield and high purity.

The invention relates to a preparation method of a standard astragalus extract, and belongs to the technical field of traditional Chinese medicine extraction. The preparation method comprises the following steps: taking radix astragali decoction pieces, adding alkaline water with the pH value of 12.0-13.0, carrying out reflux extraction for 3-5 times, filtering, merging filtrate, drying the merged filtrate under reduced pressure, freezing, carrying out vacuum drying, and crushing to obtain the standard radix astragali extract. According to the method, key parameters such as pH value, extraction temperature, extraction times and time of alkaline water extraction are controlled, so that efficient extraction and stable preparation of astragaloside and polysaccharide are realized, and a technical basis is provided for fully developing and utilizing an astragalus membranaceus medicinal material and promoting modern application of the astragalus membranaceus medicinal material.

This invention discloses a methane inhibitor based on plant functional components and its application. The inhibitor, by mass fraction (100%), comprises the following raw materials: 1.5-6% p-hydroxybenzoic acid, 0.4-2.4% astragaloside, 5-40% polyethylene glycol 4000, and 81.6-99.999% bentonite. The methane inhibitor provided by this invention uses p-hydroxybenzoic acid and astragaloside as active ingredients. Through their synergistic effect, it effectively inhibits the activity of methanogenic bacteria and the methane production pathway in the rumen of ruminants, while simultaneously improving the rumen fermentation pattern. The above-mentioned methane inhibitor uses natural plant-derived active ingredients, is safe, non-toxic, environmentally friendly, and has a simple preparation process suitable for large-scale production.

The application provides a mesenchymal stem cell cryopreservation solution and a preparation method thereof, and belongs to the technical field of cell engineering. The cryopreservation solution takes diluted DMEM as a basic culture medium, and introduces trehalose, L-proline, polyethylene glycol, sodium carboxymethyl cellulose, sodium glycine, sericin, glycerol, resveratrol and other components as additives. The cryopreservation solution formula adopts a DMSO-free and serum-free scheme, uses sodium glycine, sericin and glycerol as a composite protective agent, can effectively alleviate ice crystal damage, maintain osmotic pressure balance and protect cell membranes and protein structures, and has an effect superior to DMSO and glycerol and no cytotoxicity. In addition, the application uses resveratrol, coenzyme and astragaloside and other components as growth factors to maintain the activity of mesenchymal stem cells in a frozen state. After umbilical cord mesenchymal stem cells are cryopreserved for 2 years according to the application, the survival rate of the umbilical cord mesenchymal stem cells can reach 99.83% at most, the cell viability OD value reaches 0.96, and the cells are observed to have good adhesion and growth conditions under a microscope. △ The survival rate of the umbilical cord mesenchymal stem cells can reach 99.83% at most, the cell viability OD value reaches 0.96, and the cells are observed to have good adhesion and growth conditions under a microscope.

The invention discloses an astragaloside nano preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, dissolving astragaloside in an organic solvent to prepare an astragaloside solution as an organic phase; dissolving a stabilizer in water to prepare a stabilizer solution as a water phase; s2, the astragaloside solution and the stabilizer solution are pumped into a micro-fluidic chip from different channel inlets according to the set total flow velocity and flow velocity ratio, micro mixing is conducted, and an astragaloside nano suspension is prepared; s3, the astragaloside nano suspension is dried, and the astragaloside nano preparation is prepared.

The invention discloses a process for preparing astragaloside through multi-strain fermentation. Through segmented biotransformation, by utilizing a segmented process that in-situ enzyme production of trichoderma reesei, aspergillus oryzae deacetylation and aspergillus niger step-by-step desugaring are carried out to directionally transform upstream saponin, and bacillus subtilis and candida are used for terminal modification, astragaloside is not subjected to continuous desugaring or ring opening to obtain cycloastragenol after being formed, and the yield of astragaloside is remarkably improved.

The invention discloses a traditional Chinese medicine grease oral cream for repairing gastric mucosa and a preparation method thereof, optimizes a traditional heating extraction process into direct compatibility of traditional Chinese medicine extracts, and belongs to the technical field of traditional Chinese medicine preparations. The emulsifiable paste is prepared from a fixed-proportion grease base (20% of emu oil, 40% of olive oil, 20% of coconut oil and 20% of castor oil), six traditional Chinese medicine extract effective components (1-2% of astragaloside, 1-2% of atractylenolide, 1-2% of atractylenone, 1-2% of berberine, 1-2% of scutellaria baicalensis extract and 1-2% of obakunone), 3% of vitamin E, 20-25% of sea buckthorn seed oil and 10% of excipient beewax. According to the preparation process, heating extraction is abandoned, the problems that the extract is difficult to dissolve and easy to agglomerate in grease are solved through infiltrating the extract with a small amount of grease, homogenizing at the low temperature of 60 DEG C and shaping and fixing beewax, and uniform dispersion and stable dispersion of the extract are realized.

The invention discloses a pharmaceutical composition for cardiovascular and cerebrovascular diseases, and relates to the technical field of traditional Chinese medicines, the pharmaceutical composition comprises the following raw materials by weight: 150-250 parts of panax notoginseng saponins, 8-12 parts of ginkgo total flavonoids, 3-5 parts of dipyridamole, 80-120 parts of a salvianolic acid extract, 5-15 parts of astragaloside, 20-40 parts of a composition of saikoside a and albiflorin, and 30-50 parts of a composition of ginsenoside Rg1 and ophiopogonin D; according to the pharmaceutical composition, the system treatment rule of eliminating, clearing, lowering, warming, harmonizing and tonifying in the traditional Chinese medicine is completely and quantitatively applied to the design of the modern traditional Chinese medicine compound composition for the first time, so that the abstract theory is converted into specific quantifiable components and proportions, and the problem that the traditional compound is not clear and unclear is solved; all the components in the composition are safe components which are recorded in pharmacopoeia or are clinically used for a long time, and potential risks caused by large-dose use of a single component can be reduced through reasonable compatibility and mutual restriction.

The invention provides a preparation method of astragaloside-rADSCs hydrogel, which comprises the following steps: extracting rADSCs, culturing the rADSCs to a P3 generation, co-culturing the rADSCs cultured to the P3 generation and an astragaloside solution, and collecting supernate to obtain the astragaloside-rADSCs; the preparation method comprises the following steps: uniformly mixing PF-127 with sodium hyaluronate, then mixing with astragaloside-rADSCs, stirring, and standing, so as to obtain the astragaloside-rADSCs hydrogel. The invention further provides an application of the prepared astragaloside-rADSCs hydrogel. The astragaloside-rADSCs hydrogel is used for preparing a medicine for repairing diabetic skin injury. According to the astragaloside-rADSCs hydrogel prepared by the invention, the astragaloside is used for regulating the stem cell function and enhancing the repair promotion capability of the stem cell, serum-related risks are avoided through serum-free culture, controlled release of cell factors is realized by virtue of the temperature-sensitive hydrogel, and a brand new non-invasive, non-drug-resistant and efficient repair treatment scheme is provided for diabetic skin injury.

The invention relates to a pharmaceutical composition for treating chronic obstructive pulmonary disease and application of the pharmaceutical composition. The pharmaceutical composition is prepared from astragaloside, nobiletin and icariin. The composition disclosed by the invention is rich in raw materials, has the effects of improving airflow limitation, resisting inflammation, resisting oxidation and the like, can be effectively used for treating the chronic obstructive pulmonary disease, and has relatively high economic and social benefits.

The invention discloses a traditional Chinese medicine composition for atherosclerotic diseases, a preparation and a quality control method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition consists of 12 traditional Chinese medicines including 5-25 parts of codonopsis pilosula, 20-50 parts of astragalus membranaceus, 6-25 parts of pseudo-ginseng, 20-50 parts of salvia miltiorrhiza and the like, preferably 10 parts of codonopsis pilosula, 20 parts of astragalus membranaceus, 10 parts of pseudo-ginseng and the like. During preparation, pseudo-ginseng and coptis chinensis are separately crushed, other medicinal materials are decocted twice with water, the decoction is concentrated into extract, and auxiliary materials are added to prepare capsules, tablets and other preparations. According to quality control, panax notoginseng is identified by thin layer chromatography of an optimized developing solvent, and astragaloside content is measured by high performance liquid chromatography. The traditional Chinese medicine composition has the effects of replenishing qi to invigorate the spleen and promoting blood circulation to remove blood stasis, is stable in process and controllable in quality, and is suitable for auxiliary conditioning of qi deficiency and blood stasis type atherosclerotic diseases.

The present application relates to the technical field of cell engineering, and particularly relates to a culture medium for producing biological antibodies and a fermentation method thereof.The culture medium comprises a basic culture medium and a fermentation culture medium; the basic culture medium is based on a commercial culture medium and comprises the following components: fumaric acid, ferric ammonium citrate, astragaloside and baicalein; the fermentation culture medium is based on a commercial culture medium and comprises the following components: L-citrulline, L-ornithine, L-theanine, L-homoarginine, L-hydroxyproline, L-allo-threonine, mannose, isorhamnetin and ginkgolin.The culture medium combination can effectively improve the expression level of target antibodies, supports cells to maintain long-term activity in a high-density state; meanwhile, the charge variant distribution of the obtained antibodies is more uniform, and the product purity and consistency are significantly improved.

This invention relates to the field of biomedical materials technology, specifically to a chitosan-hyaluronic acid hydrogel composition based on astragaloside A and salvianolic acid B, its preparation method, and its applications. This hydrogel constructs a three-dimensional network of synergistic cross-linking between chitosan and hyaluronic acid, loading multiple natural active ingredients, including astragaloside A, salvianolic acid B, ferulic acid, and notoginsenoside R1, forming a composite hydrogel with good biocompatibility, controllable degradation, and anti-inflammatory and anti-adhesion functions. A maleimide-cysteine ​​system is used to achieve C-S covalent cross-linking, improving structural stability and component release efficiency. Animal experiments show that this hydrogel can significantly reduce postoperative adhesion scores and inflammatory factor levels, demonstrating broad potential for postoperative anti-adhesion applications.

The invention relates to the technical field of traditional Chinese medicine powder processing, in particular to a grinding aid special for superfine grinding of radix astragali powder and a preparation method of the grinding aid. The grinding aid is prepared from polyethylene glycol 4000, modified lecithin, a charge control agent and an antioxidant, and maltodextrin is used for complementing when the total amount is less than 100 parts; wherein the modified lecithin is prepared through 732 ion exchange resin pretreatment, soybean lecithin epoxidation and epoxy ring opening, the grinding aid is prepared through normal-temperature and normal-pressure stirring and mixing, and 1%-5% of an aqueous solution is sprayed and added to a grinding system during use. According to the grinding aid, the grinding energy consumption can be reduced, the wall sticking of equipment and powder agglomeration are reduced, the astragaloside and flavonoid active ingredients are efficiently reserved, all the components are safe and compliant, the grinding aid is suitable for processing astragalus membranaceus food and traditional Chinese medicine preparations, existing equipment does not need to be transformed, and industrialization is easy.

The invention provides application of a combination of astragaloside and lobetyolin in preparation of an anti-breast cancer drug with a synergistic interaction effect on cis-platinum. The pharmaceutical composition has the potential to be developed into a medicament for reducing toxicity and enhancing effect on cis-platinum.

The present application relates to the field of targeted drugs, and discloses a drug self-assembly system for treating chronic heart failure, and a preparation method and application thereof, the drug self-assembly system comprising: a drug active component (including astragaloside and tanshinone II A), a phosphatidylated triphenylphosphine compound and a biomimetic membrane (a product obtained after mixing of macrophage membrane fragments and myocardial cell membrane fragments); the phosphatidylated triphenylphosphine compound is embedded on the surface of nanoparticles self-assembled by the drug active component, and the biomimetic membrane is wrapped on the outer layer of the modified nanoparticles; the encapsulation rate of the drug active component in the drug self-assembly system is 80-95 wt%. The drug self-assembly system provided by the present application improves the encapsulation rate of the drug active component and can realize efficient drug delivery, has good stability and high safety, has low preparation process cost, and has good batch production and clinical transformation prospects.

The invention relates to the technical field of dietary nutrition products, and particularly discloses a dietary nutrition intervention composition for improving diabetes mellitus and a preparation method and application thereof, and the preparation method comprises the following steps: (S01) taking a proper amount of codonopsis pilosula polysaccharide and galactomannan, putting into a reaction kettle, adding water, and stirring for dissolving; (S02) continuing to add a proper amount of astragaloside, balsam pear polypeptide and mango extract into the dissolved matter in the step (S01), stirring and mixing, adding a proper amount of auxiliary carrier when the dissolved matter is in a transparent or slightly turbid state, and continuing to stir to obtain a compound liquid; (S03) performing vacuum concentration and homogeneous dispersion on the compound liquid in the step (S02) to obtain dispersion liquid; and (S04) carrying out vacuum freeze drying on the dispersion liquid obtained in the step (S03), and mixing the freeze-dried powder in a fluidized bed mixer to obtain a dietary nutrition intervention composition finished product. The invention has the characteristics of reducing blood sugar and improving intestinal flora structure and function.

The invention belongs to the technical field of analytical chemistry, and particularly relates to a method for determining the content of astragaloside IV in astragalus fine granules. The method provided by the invention is a high performance liquid chromatography method, adopts an ultraviolet detector which is most commonly used in liquid chromatography, has higher sensitivity for detecting astragaloside with lower content in a preparation, optimizes a method for preparing a test sample, enables the preparation process to be simpler and more convenient to operate, shortens the preparation time, saves the detection cost, and has a better application prospect.

This invention relates to the field of separation and purification technology, and in particular to a method for extracting and separating five compounds from the pomace of red bean and blueberry. This invention develops a microwave-ultrasound synergistic enhanced extraction coupled with carbon dioxide gas-responsive in-situ eutectic solvent targeted extraction technology, combined with macroporous resin enrichment and high-speed countercurrent chromatography separation technology, achieving efficient extraction of five monomeric components: epicatechin, astragaloside, quercetin, kaempferol, and ursolic acid. This process significantly reduces time consumption, energy consumption, and environmental pollution, providing technical support for the large-scale industrial production of red bean and blueberry resources for high-value utilization.

The invention provides a method for determining the content of multiple components in an Aidi preparation, and belongs to the technical field of medicines. The Aidi preparation is prepared from traditional Chinese medicinal materials including ginseng, cantharides, astragalus membranaceus and acanthopanax. The content determination method comprises the following steps: simultaneously determining cantharidin, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rc, ginsenoside Rd, isofraxidin, syringin, formononetin, astragaloside, chlorogenic acid, eleutheroside E, calycosin-7-glucoside, astragaloside II, neochlorogenic acid, cryptochlorogenic acid and eleutheroside E1 in the Aidi preparation by adopting liquid chromatography-mass spectrometry; the composition is prepared from effective components such as ginsenoside F3, ginsenoside Rg2, azelaic acid and the like. Compared with the prior art, the method has the advantages that the contents of the 20 effective components in the Aidi preparation are simultaneously measured under the same chromatographic condition through liquid chromatography-mass spectrometry, the method is convenient and rapid, the requirement for product quality detection is greatly improved, the method is more suitable for quality control of drugs in the future, and the drug quality and the clinical drug effect are guaranteed.